Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Has Average Price Target of $42.20 According to Brokerages

Attovia Therapeutics, Inc. (NASDAQ:ATTO) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $42.20.

ATTO has been the topic of a number of recent analyst reports. Leerink Partners initiated coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $52.00 price target on the stock. Citigroup began coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They set a “buy” rating and a $30.00 price objective for the company. Wall Street Zen upgraded shares of Attovia Therapeutics to a “sell” rating in a research note on Saturday, September 19th. Lifesci Capital assumed coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price target on the stock. Finally, Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a report on Monday, August 31st. They set an “outperform” rating and a $45.00 price objective for the company.

Insider Buying and Selling

In other Attovia Therapeutics news, major shareholder Global Strategic Fund I. Venbio purchased 382,352 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,499,984.00. Following the completion of the purchase, the insider owned 4,181,367 shares of the company’s stock, valued at approximately $71,083,239. The trade was a 10.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Redmile Group, Llc acquired 200,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were bought at an average price of $17.00 per share, for a total transaction of $3,400,000.00. Following the acquisition, the insider owned 982,854 shares of the company’s stock, valued at approximately $16,708,518. This represents a 25.55% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 2,740,587 shares of company stock valued at $47,269,979 in the last 90 days.

Attovia Therapeutics Price Performance

Shares of NASDAQ ATTO opened at $17.50 on Friday. Attovia Therapeutics has a 1-year low of $16.15 and a 1-year high of $28.00. The stock’s fifty day moving average is $20.84.

Attovia Therapeutics (NASDAQ:ATTO) last posted its earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The business had revenue of $0.45 million during the quarter. As a group, equities analysts forecast that Attovia Therapeutics will post -4.06 EPS for the current fiscal year.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc is a clinical-stage biotechnology company developing antibody-based medicines for immune-mediated and inflammatory diseases. The company uses proprietary antibody-engineering technologies to design therapies intended to modulate biological pathways involved in chronic inflammation.

Attovia’s development pipeline includes ATTO-1310, an investigational antibody therapy being advanced for atopic dermatitis and potentially other inflammatory conditions. The company’s broader research efforts focus on developing treatments that may offer targeted activity and durable effects for patients with immune-related diseases.

Attovia Therapeutics is advancing its programs through preclinical and clinical development and has not yet established a commercial product portfolio.